PREGABALIN | N021446 | UPJOHN US 2 LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2010-03-12 | Terminated 2012-12-11 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Hyman, Phelps, & McNamara, P.C. FDA-2026-P-2430 Hyman, Phelps & McNamara, P.C., on behalf of its client, filed this suitability petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Pregabalin Tablets in 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg strengths suitable for submission in an ANDA, w | Suitability | 2026-03-09 | Open | Hyman |
Suitability Petition from Lachman Consulting Services, Inc. FDA-2025-P-1135 Lachman Consulting Services, Inc. filed this suitability petition under Section 505(j)(2)(C) of the FD&C Act requesting that the FDA declare Pregabalin Orally Disintegrating Tablets in strengths of 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg suitable for submission as an ANDA, with LYRICA Capsules (NDA | Suitability | 2025-05-01 | Open | Lachman Consulting Services |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.